Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661254 | 0.88 | HAVCR2 (0.34) | PARG | |
| SCHEMBL1660973 | 0.87 | CCNK (0.37) | CCNKCDK12ADRA1AABL1PARG | |
| SCHEMBL1661015 | 0.86 | IDH1 (0.33) | — | |
| SCHEMBL2597235 | 0.86 | CCNK (0.35) | CCNKCDK12ADRA1A | |
| SCHEMBL1661007 | 0.81 | IDH1 (0.35) | PARG | |
| SCHEMBL2597205 | 0.80 | CCNK (0.31) | CCNKCDK12ABL1 | |
| SCHEMBL1661441 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL1660532 | 0.80 | IDH1 (0.33) | PARG | |
| SCHEMBL2597176 | 0.80 | CCNK (0.31) | CCNKCDK12ABL1 | |
| Selurampanel SCHEMBL1660562 | 0.79 | HAVCR2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | GRIK2, GRIK1, GRIK4 | CCNK 4128/4885CDK12 2622/4885ADRA1A 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.